About Emboline
Emboline is a Healthcare company based in Santa Cruz (United States) founded in 2011. It operates as an aortic embolic protection devices are developed for cardiovascular procedures. Emboline has raised $101.92 million across 5 funding rounds from investors including GAM Investments, ShangBay Capital and SV Tech Ventures. The company has 16 employees. Emboline offers products and services including Emboliner Catheter. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is EMBOLINE INC. Its competitors include Claret Medical, Protembis, Synaptive Medical, Filterlex Medical and Keystone Heart and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Emboline was founded in 2011 in Santa Cruz, United States, within the medical device sector. An aortic embolic protection device known as the Emboliner is developed to prevent embolic events, such as strokes, during catheter-based heart valve replacements. The device features a mesh filter deployed in the aorta, allowing procedures to proceed under protection. Operations focus on interventional cardiology applications across the United States.
- Headquarters Santa Cruz, United States
- Employees 16
- SectorsHealthcare
- Website emboline.com
- Legal Name Emboline Inc
- Total Equity Funding$101.92M (USD)
in 5 rounds
- Latest Funding Round$20M (USD), Series C
Mar 2026
- InvestorsGAM Investments
& 4 more
- Employee Count16
Products & Services of Emboline
Emboline offers a comprehensive portfolio of products and services, including Emboliner Catheter.
Catheter that captures emboli during TAVR to prevent brain lesions
Funding Insights of Emboline
Emboline has successfully raised a total of $101.92M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $20 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $101.92M
- Total Rounds 5
- Last Round Series C — $20M
- First Round $10M
(Apr 2018)
- Investors Count 5
All 5 funding rounds of Emboline with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2026 | $20M | Series C | – | – | |
| May 2021 | $55.36M | Series D | – | Matrix Capital Management | |
| Jan 2021 | $11.56M | Series C | – | – | – |
| Jan 2020 | $5M | Series B | – | – | – |
| Apr 2018 | $10M | Series B | – | ShangBay Capital, SV Tech Ventures | – |
5 investors in total: 5 institutional.
Investors in Emboline
Emboline has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include GAM Investments, ShangBay Capital and SV Tech Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
- | – | shangbaycapital.com | - | |
Life sciences and tech focused VC firm funding companies in the US and Israel | – | svtechventures.us | Palo Alto, United States | |
- | – | matrixcapitalmanagement.com | - | |
Investment management services are provided by GAM to global clients. | 1983 | gam.com | Dublin, Ireland | |
- | – | trinitycapital.com | - |
Investor details for Emboline
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Emboline
8 people are tracked at Emboline (8 in leadership); the tracked headcount is 16.
| Name | Role | Group |
|---|---|---|
Laura A. Brenton | Sr. Vice President, Clinical & Medical Affairs | Leadership |
Duda Markovic | Director Clinical Affairs at Emboline | Leadership |
Mark Caires | Chief Financial Officer | Leadership |
Eric Storne | Vice President Of Marketing And Clinical Relations | Leadership |
Amir Belson | Founder | Leadership |
Matthew Davis, PMP | Vice President Of Product Development | Leadership |
Graydon Philipps | Director Clinical Field Operations And Physician Training | Leadership |
Joshua Thielen | Director, Field Clinical & Physician Training | Leadership |
Complete people profiles for Emboline
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Emboline
3 dated milestones of Emboline across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Emboline is founded.
- Funding First funding round of $10.0M.
- Funding Latest funding round, Series C, of $20.0M.
Competitors of Emboline
Emboline has 9 listed competitors in our database, 9 of them funded. They include Claret Medical, Protembis, Synaptive Medical, Filterlex Medical and Keystone Heart, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| claretmedical.com | 2009 | Santa Rosa, United States | $47.76M | 105 | Cerebral vascular protection systems for endovascular procedures are developed. | |
| protembis.com | 2013 | Aachen, Germany | $45.17M | 3 | Manufacturer of cerebral protection device | |
| synaptivemedical.com | 2012 | Toronto, Canada | $76.83M | – | Planning and imaging solutions for neurosurgery are developed. | |
| filterlex.com | 2015 | Tel Aviv, Israel | $16.89M | – | Developer of an embolic protection device | |
| keystoneheart.com | 2004 | Tampa, United States | $14M | – | Embolic cerebral protection devices | |
| embrella.net | 2007 | Malvern, United States | $6.7M | – | Embolic cerebral protection is enhanced for cardiovascular procedures. | |
| transversemedical.com | 2011 | Golden, United States | $26.77M | – | Developer of a device to prevent stroke during transcatheter aortic valve replacement heart procedures | |
| invictusmed.com | 2010 | San Antonio, United States | $8.93M | – | Pediatric medical devices for infant care are developed and explored. | |
| neuramedica.com | 2014 | Oregon, United States | $1.85M | – | Bioabsorbable dural clips are developed for durotomy and spinal closures. |
Detailed competitors of Emboline
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Emboline
The website of Emboline (emboline.com) receives about 1.5K visits a month.
- Monthly visits1.5K
▲ 44.6% vs previous month
Top companies in Neurology
10 companies that operate in the same segment as Emboline (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | 541 | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Emboline
Complete news archive for Emboline
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Emboline
Emboline was founded in 2011 and raised its 1st funding round 7 years after it was founded.
Emboline is headquartered in Santa Cruz, United States. It is registered at Santa Cruz, California, United States.
Emboline is a funded company, having raised a total of $101.92M across 5 funding rounds to date. The company's 1st funding round was a Series B of $10M, raised on Apr 2018.
Emboline has 16 employees.
Emboline was founded in 2011 in Santa Cruz, United States, within the medical device sector. An aortic embolic protection device known as the Emboliner is developed to prevent embolic events, such as strokes, during catheter-based heart valve replacements. The device features a mesh filter deployed in the aorta, allowing procedures to proceed under protection. Operations focus on interventional cardiology applications across the United States.
Emboline's top competitors include Protembis, Synaptive Medical and Claret Medical.
Emboline offers Emboliner Catheter.
Emboline has 5 investors. Key investors include GAM Investments, ShangBay Capital, SV Tech Ventures, Matrix Capital Management, and Trinity Capital.
Emboline operates through Emboline Inc.